Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.

TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.

Following positive interim Phase I/II results, expectations are rising for SK Bioscience’s recombinant COVID-19 vaccine as it becomes the first Korea-developed candidate to progress to Phase III. 

The South Korean AI-driven drug discovery venture is vying with global rivals in the space to show concrete validation of its approaches in partnered projects, while eyeing international expansion and new fundraising, its CEO says.